Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) EBIT (2016 - 2025)

Anaptysbio (ANAB) has disclosed EBIT for 10 consecutive years, with $16.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 268.17% year-over-year to $16.3 million, compared with a TTM value of -$2.7 million through Dec 2025, up 97.61%, and an annual FY2025 reading of -$2.7 million, up 97.61% over the prior year.
  • EBIT was $16.3 million for Q4 2025 at Anaptysbio, down from $34.7 million in the prior quarter.
  • Across five years, EBIT topped out at $34.7 million in Q3 2025 and bottomed at -$44.4 million in Q1 2023.
  • Average EBIT over 5 years is -$22.7 million, with a median of -$27.7 million recorded in 2022.
  • The sharpest move saw EBIT crashed 5115.57% in 2022, then surged 268.17% in 2025.
  • Year by year, EBIT stood at -$31.2 million in 2021, then rose by 16.64% to -$26.0 million in 2022, then crashed by 62.23% to -$42.1 million in 2023, then skyrocketed by 77.05% to -$9.7 million in 2024, then soared by 268.17% to $16.3 million in 2025.
  • Business Quant data shows EBIT for ANAB at $16.3 million in Q4 2025, $34.7 million in Q3 2025, and -$26.2 million in Q2 2025.